Request for Comments

In accordance with the Paperwork Reduction Act, comments on AHRQ’s information collection are requested with regard to any of the following: (a) Whether the proposed collection of information is necessary for the proper performance of AHRQ’s health care research and health care information dissemination functions, including whether the information will have practical utility; (b) the accuracy of AHRQ’s estimate of burden (including hours and costs) of the proposed collection(s) of information; (c) ways to enhance the quality, utility and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information upon the respondents, including the use of automated collection techniques or other forms of information technology.

Comments submitted in response to this notice will be summarized and included in the Agency’s subsequent request for OMB approval of the proposed information collection. All comments will become a matter of public record.

Karen J. Migdal,
Chief of Staff.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

CENEF FOR DISEASE CONTROL AND PREVENTION

Advisory Committee on Immunization Practices (ACIP)

AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Notice of meeting.

SUMMARY: In accordance with the Federal Advisory Committee Act, the Centers for Disease Control and Prevention (CDC), announces the following meeting of the Advisory Committee on Immunization Practices (ACIP). This meeting is open to the public, limited only by room seating. Time will be available for public comment. The public is welcome to submit written comments in advance of the meeting. Comments should be submitted in writing by email to the contact person listed below. The deadline for receipt is February 14, 2018. Written comments must include full name, address, organizational affiliation, email address of the speaker, topic being addressed and specific comments. Written comments must not exceed one single-spaced typed page with 1-inch margins containing all items above. Only those written comments received 10 business days in advance of the meeting will be included in the official record of the meeting. Public comments made in attendance must be no longer than 5 minutes and the person giving comments must attend the public comment session at the start time listed on the agenda. Time for public comments may start before the time indicated on the agenda. The meeting will be webcast live via the World Wide Web; for instructions and more information on ACIP please visit the ACIP website: http://www.cdc.gov/vaccines/acip/index.html.

DATES: The meeting will be held on February 21, 2018, 8:00 a.m. to 5:45 p.m., EDT, and February 22, 2018, 8:00 a.m. to 12:30 p.m., EDT.

ADDRESSES: CDC, 1600 Clifton Road, NE; Tom Harkin Global Communications Center, Kent ‘Oz’ Nelson Auditorium, Atlanta, Georgia 30329.

FOR FURTHER INFORMATION CONTACT: Stephanie Thomas, ACIP Committee Management Specialist, CDC, NACR. Email ACIP@cdc.gov.

SUPPLEMENTARY INFORMATION: Purpose: The committee is charged with advising the Director, CDC, on the use of immunizing agents. In addition, under 42 U.S.C. 1396s, the committee is mandated to establish and periodically review and, as appropriate, revise the...
list of vaccines for administration to vaccine-eligible children through the Vaccines for Children (VFC) program, along with schedules regarding dosing interval, dosage, and contraindications to administration of vaccines. Further, under provisions of the Affordable Care Act, section 2713 of the Public Health Service Act, immunization recommendations of the ACIP that have been approved by the Director of the Centers for Disease Control and Prevention and appear on CDC immunization schedules must be covered by applicable health plans.

Matters To Be Considered: The agenda will include discussions on Influenza vaccines, evidence based recommendations, anthrax vaccine, Japanese encephalitis vaccines, hepatitis vaccines, human papillomavirus vaccines, pneumococcal vaccines, meningococcal disease, and an update on vaccines and other biologics for prevention and treatment of healthcare-associated infections. A recommendation vote is scheduled for hepatitis vaccines and evidence based recommendations. Agenda items are subject to change as priorities dictate.

The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 2018–02268 Filed 2–5–18; 8:45 am]
BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Service Administration

Advisory Committee on Heritable Disorders in Newborns and Children

AGENCY: Health Resources and Service Administration (HRSA), Department of Health and Human Services (HHS).

ACTION: Notice; correction.

SUMMARY: This notice announces a correction to the meeting announcement for a public meeting of the Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC), published in the Federal Register on January 22, 2018. The meeting has changed from a two-day meeting to a one-day meeting, to be held on Thursday, February 8, 2018. Agenda items have been updated and will include a final evidence-based review report on the spinal muscular atrophy (SMA) condition nomination for possible inclusion on the Recommended Uniform Screening Panel (RUSP). Following this report, the ACHDNC expects to vote on whether to recommend adding SMA to the RUSP to the Secretary of HHS. The agenda will also include presentation of a document on cutoff determinations and risk assessment methods used for dried bloodspot newborn screening. The Committee expects to vote on whether to support this document. The ACHDNC members will also consider a report on Quality Measures in Newborn Screening from the Follow up and Treatment Workgroup. HRSA will post the agenda two days prior to the meeting on the Committee’s website: https://www.hrsa.gov/advisory-committees/heritable-disorders/index.html. Please note that agenda items are subject to changes as priorities dictate.

DATES: Thursday, February 8, 2018, from 8:30 a.m. to 3:00 p.m. ET (meeting time is tentative).

ADDRESSES: The address for the meeting is 5600 Fishers Lane, 5th Floor Pavilion, Rockville, MD 20857. Participants may also access the meeting through Webcast. Advanced registration is required. Please register online at http://www.achdncmeetings.org/ by 12:00 p.m. ET on February 5, 2018. Instructions on how to access the meeting via Webcast will be provided upon registration.

Please note that the 5600 Fishers Lane building requires security screening on entry. Visitors must provide a driver’s license, passport, or other form of government-issued photo identification or they cannot enter the facility. Per the original meeting notice, non-US Citizens planning to attend in person had to provide additional information to HRSA by January 24, 2018, 12:00 p.m. Eastern Time.

FOR FURTHER INFORMATION CONTACT: Anyone requesting information regarding the ACHDNC should contact Ann Ferrero, Maternal and Child Health Bureau (MCHB), HRSA, in one of three ways: (1) Send a request to the following address: Ann Ferrero, MCHB, HRSA 5600 Fishers Lane, Room 18N100C, Rockville, MD 20857; (2) call 301–443–3999; or (3) send an email to: AFerrero@hrsa.gov.

Correction: Date and time of the ACHDNC’s public meeting. The meeting will now be held on Thursday, February 8, 2018, from 8:30 a.m. to 3:00 p.m. ET.

Amy McNulty,
Acting Director, Division of the Executive Secretariat.

[FR Doc. 2018–02279 Filed 2–5–18; 8:45 am]
BILLING CODE 4165–15–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Minority Health and Health Disparities; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable materials, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute on Minority Health and Health Disparities Special Emphasis Panel; Special Emphasis Panel (R13) Conferences Grants.

Date: March 16, 2018.

Time: 1:00 p.m. to 4:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health NIMHD, 7201 Wisconsin Ave., Suite 533, Bethesda, MD 20814.

Contact Person: Richard C. Palmer, DRPH, Health Scientist Administrator, National Institute on Minority Health and Health Disparities, National Institutes of Health, 7201 Wisconsin Ave, Bethesda, MD 20814, (301) 451–2432, richard.palmer@nih.gov.


David Clary,
Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2018–02279 Filed 2–5–18; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as